Skip to content

A Clinical Trial to Evaluate the effect of an Ayurvedic Regimen administered in (COVID â?? 19) Patients

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the effect of an Ayurvedic Regimen administered in nCoV-2 (COVID â?? 19) Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027882
Enrollment
150
Registered
2020-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B338- Other specified viral diseases

Interventions

Intervention1: Ayurvedic Regimen: Divya Swasari Vati 2 tablets orally with luke-warm water, thrice a day, half an hour before the breakfast, lunch and dinner. Divya Coronil Tablet2 tablets orally wit

Sponsors

Patanjali Research Institute
Lead Sponsor
Swami Vivekanand Subharti University
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Age 18- 60 years of both male and female gender. Laboratory confirmed COVID-19 patients determined through (RT-PCR). Patient consenting to participate in the study and follow instructions. Agree to attend hospital for follow up on predetermined schedule.

Exclusion criteria

Exclusion criteria: Laboratory confirmed COVID-19 asymptomatic cases. Patients on parenteral nutrition. Pregnant and lactating mothers and those who have pregnancy plan. Person with serious critical illness like End stage liver or renal disease, Coronary artery disease, Stroke or Renal tubular acidosis. Participants with any immunosuppressive medication or in an immune compromised state or hematological disease.Patients on any kind of Ayurveda treatment or any other alternative and complementary medicinal systems such as Homeopathy, Unani, Siddha and in particular requiring oral therapy of any kind.

Design outcomes

Primary

MeasureTime frame
To render proportion of patient showing clinical improvement in mild, moderate and severe COVID-19 cases. Mean time (days) for clinical recovery. Timepoint: Details will be recorded on Day 0 i.e. the day of admission (baseline), Day 3, Day 7 ,Day 14 and on one follow up visit on Day 28.

Secondary

MeasureTime frame
To restore health and reduction in serum viral load. Rate of patients with negative SARS-CoV2 on nasal or throat swab RT-PCR test. Reduction in increased immunological markers like IL6 and other relevant markers like quantitative CRP, Serum LDH, TLC. â?¢ Drug related side effects and toxicity, and tolerability. Health status improvement in Quality of life through WHO QOL bref questionnaire. Timepoint: Details will be recorded on Day 0 i.e. the day of admission (baseline), Day 3, Day 7 ,Day 14 and on one follow up visit on Day 28.

Countries

India

Contacts

Public ContactDr Gaurav Kapil

Subharti Medical College and Hospital

shirobhisharma@yahoo.in9456206192

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026